6 results about "Cutaneous wound" patented technology

Concentrating devices, systems, and methods include those for separating fluids to be sensed (e.g., analytes, such as volatile organic compounds (VOCs) and / or other chemical substances) from other fluid (e.g., a carrier gas, air, etc.) of a fluid mixture received from a target area of a subject's anatomy (e.g., a subject's skin, a wound on a subject, etc.). In some cases, the concentration system may include a housing and a rotor positioned in a compartment of the housing. The housing may receive a fluid mixture in the compartment and rotation of the rotor relative to the housing may separate fluid to be sensed in the fluid mixture from other fluid of the fluid mixture.

Concentrating devices, systems, and methods include those for separating fluids to be sensed (e.g., analytes, such as volatile organic compounds (VOCs) and / or other chemical substances) from other fluid (e.g., a carrier gas, air, etc.) of a fluid mixture received from a target area of a subject's anatomy (e.g., a subject's skin, a wound on a subject, etc.). In some cases, the concentration system may include a housing and a rotor positioned in a compartment of the housing. The housing may receive a fluid mixture in the compartment and rotation of the rotor relative to the housing may separate fluid to be sensed in the fluid mixture from other fluid of the fluid mixture.

Provided is a recombinant fibronectin fusion protein comprising a recombinant fibronectin mutant and platelet factor 4, wherein the recombinant fibronectin fusion protein has an amino acid sequence as set forth in SEQ ID NO: 3 or SEQ ID NO: 4, and a molecular weight of not more than 90 kDa. The recombinant fibronectin fusion protein exhibits good solubility, has a simple preparation process, and is conveniently purified. The recombinant fibronectin fusion protein comprises a new recombinant fibronectin, and can inhibit inflammation during wound healing, and promote cutaneous wound healing in mice. When platelet factor 4 is fused to the N-terminus of the recombinant fibronectin mutant, cell proliferation activity can be significantly and effectively enhanced.

The present invention relates to the therapeutic use of a composition for the treatment of cutaneous wounds such as acute wounds, chronic wounds or epidermolysis bullosa wounds. The composition according to the invention is based on ABA-type triblock copolymers, comprising two thermoplastic styrene end blocks A and an elastomeric central block B which is a saturated olefin, comprising at least one resin selected from aromatic resins usable in particular for producing an interface dressing with a framework or support or self-supporting.

Aspects of embodiments of the present disclosure relate to compositions and methods for treating wounds and / or promoting wound healing, as well as for regenerating injured mammalian nerves. Additionally, the present invention relates to the application of a therapeutically effective amount of an endothelin-B receptor agonist. In particular, the present application relates to a method for treating skin or cutaneous wounds and injured cranial or peripheral nerves using IRL-1620 (sovateltide). The composition may include an endothelin-B receptor agonist, including a peptide such as sovateltide (IRL-1620). Delivery systems are also described, including gels, sponges, gauze, and meshes incorporating the drug for topical application.